Check-Cap (NASDAQ:CHEK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note released on Wednesday morning. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Trading Down 2.2 %

CHEK stock opened at $2.20 on Wednesday. The firm has a 50-day moving average of $2.26 and a two-hundred day moving average of $2.52. Check-Cap has a 12 month low of $1.30 and a 12 month high of $4.63. The company has a market cap of $12.87 million, a price-to-earnings ratio of -0.73 and a beta of 0.45.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.